0001567619-21-011941.txt : 20210609 0001567619-21-011941.hdr.sgml : 20210609 20210609181254 ACCESSION NUMBER: 0001567619-21-011941 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210607 FILED AS OF DATE: 20210609 DATE AS OF CHANGE: 20210609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dillon Michael P. CENTRAL INDEX KEY: 0001777415 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38915 FILM NUMBER: 211006268 MAIL ADDRESS: STREET 1: C/O IDEAYA BIOSCIENCES, INC. STREET 2: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc. CENTRAL INDEX KEY: 0001676725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474268251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-6209 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Ideaya Biosciences, Inc. DATE OF NAME CHANGE: 20160609 4 1 doc1.xml FORM 4 X0306 4 2021-06-07 0 0001676725 IDEAYA Biosciences, Inc. IDYA 0001777415 Dillon Michael P. C/O IDEAYA BIOSCIENCES, INC. 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, Chief Scientific Officer Common Stock 2021-06-07 4 M 0 1500 6.92 A 100289 D Common Stock 2021-06-07 4 S 0 1500 20.2221 D 98789 D Stock Option (right to buy) 6.92 2021-06-07 4 M 0 1500 0.00 D 2030-02-20 Common Stock 1500 51000 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. This transaction was executed in multiple trades in prices ranging from $19.95 to $20.495, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Jason Throne, as Attorney-in-Fact for Michael P. Dillon 2021-06-08